MBX Biosciences, Inc. (MBX) Form 8-K — Oct 22, 2026
MBX Biosciences appointed Peter Radovich to its board of directors as a Class I director, effective October 20, 2026, expanding the board to eight members. Radovich was determined independent under Nasdaq listing standards, will serve until the 2028 Annual Meeting, and received an initial stock option grant for 18,200 shares plus standard cash director compensation.
Key figures
- Board size
- 8
- Director class
- Class I (term to 2028 Annual Meeting)
- Director stock option shares
- 18200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.